The relationship between real-world inhaled corticosteroids adherence and asthma outcomes:a multilevel approach by ,
The relationship between real-world inhaled corticosteroids adherence and asthma outcomes: a multilevel approach

Marcia Vervloet PhD1*, Liset van Dijk PhD1,2, Peter Spreeuwenberg MSc1, David Price FRCGP3,4, Alison Chisholm MPH5, Eric Van Ganse MD, PhD6,7,8, Hilary Pinnock MD, MRCGP9, Cynthia S. Rand MD, PhD10, Michelle N. Eakin PhD10, Tjard Schermer PhD1,11, Patrick C. Souverein PhD12, Alexandra L. Dima PhD6; on behalf of the Respiratory Effectiveness Group’s Adherence Working Group

1 Nivel, Netherlands institute for health services research, Utrecht, the Netherlands
2 Department of PharmacoTherapy, -Epidemiology & -Economics (PTEE), Groningen Research Institute of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Groningen, Groningen, The Netherlands
3 Observational and Pragmatic Research Institute, Singapore, Singapore
4 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
5 Respiratory Effectiveness Group, Cambridge, United Kingdom
6 Health Services and Performance Research (HESPER), Claude Bernard University, Lyon, France
7 Pharmaco Epidemiology Lyon (PELyon), France
8 Respiratory Medicine, Croix-Rousse University Hospital, Lyon, France
9 Asthma UK Centre for Applied Research, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom
10 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore Maryland, USA
11 Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands
12 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

* Corresponding author (Address: P.O. Box 1568, 3500 BN Utrecht, the Netherlands; Email: M.Vervloet@nivel.nl (​mailto:M.Vervloet@nivel.nl​); Tel.: +31 30 2729713)

Email addresses coauthors:
Liset van Dijk: L.vanDijk@nivel.nl (​mailto:L.vanDijk@nivel.nl​)
Peter Spreeuwenberg: P.Spreeuwenberg@nivel.nl (​mailto:P.Spreeuwenberg@nivel.nl​)
David Price:  dprice@opri.sg (​mailto:dprice@opri.sg​) 
Alison Chisholm: achisholm2@gmail.com (​mailto:achisholm2@gmail.com​) 
Eric Van Ganse:  eric.van-ganse@univ-lyon1.fr (​mailto:eric.van-ganse@univ-lyon1.fr​) 
Hilary Pinnock:  hilary.pinnock@ed.ac.uk (​mailto:hilary.pinnock@ed.ac.uk​) 
Cynthia S. Rand: crand@jhmi.edu (​mailto:crand@jhmi.edu​) 
Michelle N. Eakin: meakin1@jhmi.edu (​mailto:meakin1@jhmi.edu​)  
Tjard Schermer: T.Schermer@nivel.nl (​mailto:T.Schermer@nivel.nl​)  
Patrick C. Souverein: p.c.souverein@uu.nl (​mailto:p.c.souverein@uu.nl​) 
Alexandra L. Dima: alexandra.dima@univ-lyon1.fr (​mailto:alexandra.dima@univ-lyon1.fr​) 

Funding 
This study was funded by the Respiratory Effectiveness Group, an international,
investigator-led, not-for-profit, real-life respiratory research and advocacy initiative (http://www.effectivenessevaluation.org (​http:​/​​/​www.effectivenessevaluation.org​/​​)). The dataset was provided by Optimum Patient Care Ltd as a donation in kind.

Conflict of Interest statement
M. Vervloet and L. van Dijk received funding for research unrelated to this study from Pfizer, AbbVie and AstraZenica. D. Price has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. E. van Ganse reports personal fees from AstraZeneca, grants and personal fees from Bayer, grants and personal fees from BMS, personal fees from Boehringer Ingelheim, grants from GlaxoSmithKline, personal fees from IQVIA, grants and personal fees from Merck Sharp and Dohme, personal fees from PELyon,  outside the submitted work. P.C. Souverein has received research support from the Respiratory Effectiveness Group. C.S. Rand serves as a member of Scientific Advisory Boards for Teva Pharmaceuticals and Glaxo Smith Kline. T. Schermer received funding for research unrelated to this study from GlaxoSmithKline and Boehringer Ingelheim. P. Spreeuwenberg, A. Chisholm, M.N. Eakin, H. Pinnock and A.L. Dima have no conflicts of interest to declare.

Word count body text: 3670
Word count abstract: 250
Number of tables: 3 




Low inhaled corticosteroids (ICS) adherence is associated with increased asthma burden. This relationship is likely bidirectional, and may vary across adherence stages (initiation, implementation, persistence). Studies rarely examine reciprocal influences. 
Objective 
To investigate the relationship between ICS implementation and asthma-related outcomes across two years, considering bidirectionality and temporal sequence.
Methods
Primary care records (1987–2012) from the Optimum Patient Care Research Database, United Kingdom, were used. Eligible patients had ≥3 years continuous registration starting 1 year before ICS initiation (index date), physician-diagnosed asthma, ≥6 years, ≥2 ICS and/or short-acting beta-agonists (SABA) prescriptions each follow-up year, no long-acting beta-agonists, leukotriene receptor antagonists or maintenance oral corticosteroids in the preceding year . ICS implementation (percentage of days covered) and risk domain asthma control (RDAC; no asthma-related hospitalizations, emergency visits, or outpatient visits,  no oral corticosteroid or antibiotic prescriptions with evidence of respiratory review) were estimated for each prescription interval (period between two successive prescriptions). Multilevel analyses modeled bidirectional relationships between ICS implementation and RDAC (and its components), controlling for socio-demographic and clinical characteristics.
Results
In prescription data from 10,472 patients, ICS implementation in the preceding interval did not predict RDAC, but was weakly positively associated with simultaneous RDAC. Being male, non-current smoker, without COPD diagnosis and <4 comorbidities significantly increased odds of RDAC. Asthma-related antibiotics and outpatient visits in the same interval, and SABA overuse in the preceding and same interval predicted lower ICS implementation. 
Conclusions 




1.	What is already known about this topic? Adherence to inhaled corticosteroids (ICS) is suboptimal. The relationship between ICS adherence and asthma outcomes is complex, as it may vary between adherence stages and is likely bidirectional. This bidirectionality is rarely investigated. 
2.	What does this article add to our knowledge? Better ICS use (implementation) was weakly associated with risk domain asthma control (RDAC) within the prescription interval. RDAC was associated with higher ICS implementation within the same interval. SABA overuse strongly predicted lower ICS implementation.









RDAC: risk domain asthma control
OPCRD: Optimum Patient Care Research Database
IPD: index prescription date
SABA: short-acting beta-agonists
LABA: long-acting beta-agonists 
OCS: oral corticosteroids 
BMI: body mass index 
MLA: multilevel analyses 
COPD: chronic obstructive pulmonary disease
GERD: gastroesophageal reflux disease
Introduction

Despite the well-established effectiveness of inhaled corticosteroids (ICS) treatment in achieving asthma control and reducing frequency and severity of asthma exacerbations (1), patients’ adherence to ICS medication is often suboptimal  ADDIN EN.CITE (2-5), which has been associated with increased individual and societal asthma burden  ADDIN EN.CITE (6, 7). The relationship between adherence to ICS medication and asthma outcomes, however, is complex. Whereas a recent systematic review showed that a higher level of ICS adherence is associated with lower risk of asthma exacerbations  ADDIN EN.CITE (8), other observational studies concluded that higher adherence levels are associated with increased use of reliever medication  ADDIN EN.CITE (9) or even an increased risk of asthma exacerbations (10). This might be caused by clinicians selectively encouraging ICS use in people at risk of exacerbations. It might also be caused by patients adjusting their therapy – reducing daily dose during periods of milder (and/or better controlled) disease and increasing daily dose during periods of greater medication dependence and less well-controlled disease. In long-term care, changes in adherence may impact asthma outcomes, which may in turn influence adherence as patients adapt their medication intake. 
A better understanding of this relationship could help identify intervention targets and inform the development of more effective interventions to improve routine care ICS use and related asthma outcomes. 






This was a retrospective observational study using electronic medical records from the Optimum Patient Care Research Database (OPCRD; https://opcrd.co.uk), a research-quality database containing patient records from primary care practices across the United Kingdom (UK). In the UK, asthma management is centralized in primary care where prescriptions are issued for each medication refill. Thus, prescribing records are in good agreement with dispensation records in the UK  ADDIN EN.CITE (15, 16). The OPRCD database provides a valuable source of longitudinal observational data for asthma research. The OPCRD is a respiratory audit database, which ensures similar registration procedures across primary care practices in the UK. At the time of data extraction, in 2012, it contained data for approximately 350,000 patients with asthma collected from more than 350 practices across the UK that had subscribed to OPC Clinical Service Evaluation. The clinical evaluation involves a combined review of electronic medical records and patients’ responses to disease-specific questionnaires. The OPRCD has been approved by Trent Multicentre Research Ethics Committee for clinical research. 

Study population
Data on ICS initiations between April 1987 and February 2012 were available. The study considered a continuous 3-year period: a baseline year, which was defined as one year prior to the index prescription date (IPD) at which patients received their first ICS prescription (ICS initiation), and two follow-up years after the IPD. All patients with at least one prescription for an ICS and 3-years of continuous history (one year before and two years after IPD) were selected. From this source population, patients were included in the study if they: (1) had received a physician-diagnosis of asthma (Read-code diagnosis, which is a coding standardized by the Quality and Outcome Framework in the UK) at least one year prior to IPD; (2) were aged ≥6 years at IPD (i.e. ≥5 years at time of asthma diagnosis); (3) initiated  ICS via metered dose inhaler or dry powder inhaler; (4) were on active asthma therapy throughout the 2-year follow-up period, defined as ≥2 prescriptions for ICS and/or short-acting beta-agonists (SABA) at different points in each year. Patients were excluded if they received any prescriptions for long-acting beta-agonists (LABA), combination ICS/LABA, and/or leukotriene receptor antagonists during the baseline year or were receiving maintenance oral corticosteroids (defined as either a prescription for 1 mg tablets or at least 7 prescriptions over the year for a daily prescribed dose of at least 10 mg) during the baseline year.

This resulted in a final study cohort of 27,185 patients. The data preparation pre-study performed  accuracy and quality checks (e.g. missing dosing instructions, missing asthma diagnosis, non-valid asthma diagnosis dates or non-valid prescription dates) through which a subset of 13,922 patients with data of sufficiently high quality and complete data for use in this study were identified  ADDIN EN.CITE (17). Records not appropriate for longitudinal ICS implementation analysis (e.g. only one prescription of ICS) or suggestive of miscoding (e.g. exceptionally high ICS dosing or prescription frequency) or that prevented evaluation of prescribed ICS dose (e.g. multiple ICS-containing products in a single prescription) were also excluded (Figure 1). A total of 10,472 patients were included in the longitudinal analyses. 

Study outcomes
ICS implementation (per-prescription interval)
To study ICS usage over time, we focused on ICS implementation, which is one of the three stages of adherence. It is recommended to distinguish these stages (being (1) initiation, (2) implementation and (3) discontinuation) in analyzing and reporting adherence to medication, since they depict different types of behavior  ADDIN EN.CITE (12). We first identified prescription intervals, being the period between two successive ICS prescriptions. ICS implementation, expressed as a percentage of days covered by the prescription based on quantity, dosage and duration, was computed for each prescription interval. Possible carryover from the previous prescription was taken into account. Figures 2a and 2b illustrate the prescription intervals and ICS implementation computation.
Three types of prescription intervals were identified in the database: (1) gap intervals, for which the number of days between the end of the supply of the first prescription and the start of the next exceeded 90 days (an acceptable cut-off point according to Souverein et al  ADDIN EN.CITE (17)). In these intervals ICS implementation equaled 0, assuming the medication was not used and thus indicating a treatment interruption; (2) intervals with 100% implementation, which are mainly intervals that are either censored at the end of the two-year-period, or intervals that preceded a gap interval; (3) intervals for which a prescription was issued within 90 days of the previous prescription and in which ICS implementation varied between 1-99%. Since we aimed to investigate the bidirectional relationship between ICS implementation and asthma-related outcomes, we excluded patients who discontinued their treatment (indicated by the gap intervals). We also excluded the 100% implementation intervals, because most of these intervals preceded a gap interval. It is highly unlikely to assume that patients took their medication perfectly during these intervals. Inclusion of only those intervals in which a variation in implementation is seen provides a more robust analysis. Moreover, it might better resemble how clinicians detect nonadherence (identifying a delay between two successive prescriptions). Refill delays identified from EMRs has also been the trigger for an adherence improving intervention in a large American study which showed modest but significant effects  ADDIN EN.CITE (18).
In the lagged analysis, however, the implementation estimates of the previous interval were included, regardless of whether this was a gap or 100% interval. From the total dataset with 94,498 intervals, 14,425 gap intervals (15.3%) and 55,971 with an implementation of 100% (59.2%) were excluded, resulting in a dataset for analysis of 24,102 intervals (25.5%) from 10,472 patients with ICS implementation ranging from 4.0% to 99.6%.

Risk domain asthma control 
In addition to ICS implementation, a composite database measure of risk domain asthma control (RDAC) for each prescription interval was computed. RDAC was defined as a composite of the following aspects of asthma-related healthcare resource utilization: asthma-related hospitalizations; emergency visits; outpatient attendances; prescriptions for asthma-related acute oral corticosteroids (OCS) and prescriptions for antibiotics with evidence of a respiratory-related consultation  ADDIN EN.CITE (14). For a patient to be controlled corresponding to this definition of RDAC, they had to have no evidence of moderate to severe asthma exacerbations (i.e. no asthma-related hospitalizations or emergency visits or OCS prescriptions) in their follow-up records and no evidence of asthma-related antibiotic prescriptions or outpatient attendances  ADDIN EN.CITE (14). RDAC is thus a binary outcome, where value 1 indicates that no exacerbations nor asthma-related antibiotic prescriptions or outpatient visits occurred in the interval, and value 0 indicates otherwise. 

Other measurements
The following descriptive characteristics were considered as potential confounders: therapeutic prescribing history data for all conditions for the three-year period: age; gender; body mass index (BMI); smoking status; and comorbid conditions, including diagnoses of other allergic and respiratory diseases. The Charlson Comorbidity Index  ADDIN EN.CITE (19), including 17 categories of comorbidities weighted based on their association with one-year all-cause mortality, was calculated during the baseline year. BMI and smoking status (current, past and never) were based on the values recorded closest to the IPD in the year before and the year after IPD. Use of short-acting beta-agonists during the year before IPD, and asthma-related antibiotic and oral steroid use was dichotomized as use versus non-use. The Index of Multiple Deprivation (20) was used as a marker for socioeconomic status, based on seven domains of deprivation: income; employment; health deprivation and disability; education, skills and training; barriers to housing and services; crime and disorder; and living environment. This is a composite index of relative deprivation at small area level, with five quintiles (Q1 = most affluent to Q5 = most deprived).

Data analyses
Multilevel analyses (MLA) were performed to take into account clustering effects of prescriptions within patients and in turn patients within general practices. Two separate MLA were performed using multilevel regression models (see Figure 3). The first evaluated the extent to which RDAC could be explained by ICS implementation and overuse of SABA within the same interval and the previous interval, and whether patient and ICS characteristics influenced this. Overuse of SABA was defined as >200 mcg of salbutamol or >500 mcg of terbutaline over the 6-month period before the end of each interval as it was not event occurrence, but a property of a longer time interval. The second MLA evaluated the extent to which ICS implementation could be explained by simultaneous and lagged RDAC (or RDAC components) and overuse of SABA, and whether patient and ICS characteristics influenced this. Each MLA model consisted of three levels: general practice, patient, and prescription interval. 

In the first MLA with RDAC as dependent variable, the following interval, patient and ICS characteristics were added to the model (Model 1):
(i)	Interval characteristics: SABA overuse (yes/no), ICS implementation (continuous).
(ii)	Patient characteristics: age (continuous), gender (dichotomous), BMI (underweight, <18.5; normal, 18.5–25; overweight, 25–30; obese, ≥30; missing), smoking history (current; none; former; missing), deprivation (Q1, most affluent; Q2; Q3; Q4; Q5, most deprived; missing), Charlson Comorbidity Index (low, ≤4; high, >4), and prior diagnosis of rhinitis, allergic rhinitis, hay fever, gastroesophageal reflux, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), and/or another respiratory disease (yes/no).
(iii)	ICS characteristics: number of doses in the inhaler device (continuous), prescribed daily dose (continuous), inhaler device type (MDI; DPI; breath-actuated inhaler (BAI); missing)

The second MLA had ICS implementation as dependent variable. Two models were studied to evaluate the effect of RDAC as a composite variable as well as the individual contributions of the disaggregate components of RDAC on implementation: 
a)	Interval (RDAC components and SABA overuse), patient and ICS characteristics (Model 2A)
b)	Interval (RDAC and SABA overuse), patient and ICS characteristics (Model 2B). 

The interval characteristics added in Model 2A were: SABA overuse (yes/no), occurrence of one or more (yes/no) of the following events: asthma-related hospitalizations; respiratory-related hospitalizations; asthma-related hospitalizations and emergency visits; acute oral corticosteroids prescriptions issued; antibiotic prescriptions with respiratory-related consultation issued; asthma-related outpatient visits; moderate to severe exacerbations. The same patient and ICS characteristics were added as described for the first MLA (Model 1). In Model 2B, the interval characteristics SABA overuse (yes/no) and RDAC (yes/no) were added, besides the same patient and ICS characteristics.








Almost half of the patients were male, and the mean age was 39.2 years (Table 1). Excluded patients were older, more deprived, had a higher BMI, had more comorbidities, were more often diagnosed with COPD or GERD, and had used more medication during the previous year (except for beta blockers). However, the absolute differences in the characteristics between the included and excluded patients appear to be small. Average level of ICS implementation was 65.2 (SD:19.7).

Risk domain asthma control
The first MLA (Table 2) reveal that only ICS implementation within the same interval was weakly positively associated with RDAC; prior ICS implementation had no effect. Several patient characteristics had an apparent influence on RDAC. Odds for being controlled in terms of RDAC (i.e. no asthma-related healthcare utilization) were 58% higher for men than for women and respectively 47% and 61% higher for non-smokers and former smokers  than for current smokers. In patients without COPD the odds of being controlled in terms of RDAC were 48% higher than in patients with a comorbid COPD diagnosis. Patients with four or fewer comorbidities were 35% more likely to be controlled in terms of RDAC than patients with five or more co-existing conditions. Finally, a higher prescribed number of daily ICS doses was associated with 7% higher odds of being controlled in terms of RDAC than a lower prescribed number of daily doses. 

ICS implementation





The aim of this study was to investigate the bidirectional relationship between routine care use of ICS (implementation) and RDAC (a database measure of asthma-related healthcare utilization). It was found that higher ICS implementation within the same prescription interval was only weakly positively associated with RDAC, ICS implementation in the preceding interval had no apparent effect on RDAC. SABA overuse in the same or preceding interval was not associated with RDAC, but some patient characteristics (gender, smoking history, COPD diagnosis and the number of comorbidities) did have an effect as well as the number of prescribed ICS daily doses. The latter in line with prior literature on determinants of adherence  ADDIN EN.CITE (22).
The lack of an association between ICS implementation and RDAC in subsequent intervals suggests that patients may adapt their medication use based on their current needs in ways that do not appear to have a major impact on their asthma-related healthcare utilization. This adaptation of therapy can not only be viewed in terms of symptoms, but also in terms of patient goals: a recent study showed that patients adapt their medication to reach their desired goals for a functional day  ADDIN EN.CITE (23). Patients strive for autonomy; for achieving a greater level of personal control over their asthma  ADDIN EN.CITE (24). Supported self-management of asthma has already shown beneficial in reducing hospitalizations, emergency visits and unscheduled consultations  ADDIN EN.CITE (25). Moreover, a recent study has shown that a personalized self-management plan encouraging increasing the dose of ICS medication temporarily when asthma control starts to deteriorate resulted in fewer asthma exacerbations  ADDIN EN.CITE (26), indicating that symptom-based ICS use is non-inferior to daily use.

Furthermore, it was found that overusing SABA within the same and previous interval was a predictor of low ICS implementation. RDAC was only associated with higher ICS implementation in the same interval, RDAC in the prior interval had no effect on implementation. An antibiotic prescription and asthma-related outpatient visits within the same interval were also associated with lower ICS implementation as did several patient characteristics, the most significant being presence of a diagnosis of COPD, and the prescribed number of daily dosages.
The significant link between prior and simultaneous SABA overuse and lower ICS implementation indicates that patients may overuse their reliever medication to manage symptoms as an alternative to regular ICS use. This might however worsen their asthma overtime. A study of Reddel et al alarmingly showed that patients were more likely to use their reliever medication to manage worsening asthma themselves rather than go to the doctor  ADDIN EN.CITE (27). Inappropriate use of reliever medication, however, while controller medication is not adequately used, has been associated with negative health outcomes and increased healthcare utilization  ADDIN EN.CITE (28-30). 

Strengths & limitations 
As asthma is a variable condition, clinical outcomes and patient self-management behaviors vary substantially and may influence each other over time. Database studies usually examine this relationship cross-sectionally, which does not offer the possibility to study reciprocal influences over time. To address this limitation, we opted for a novel design which allowed us to test both simultaneous and sequential relationships, which is an important strength of this study. Moreover, by considering implementation within individual prescription intervals, rather as an average over the study, we identified variations in ICS usage and used this more granular data to evaluate the effect of changing implementation behaviors on concurrent and subsequent asthma-related healthcare utilization. In addition, it resembles the clinical situation in which a healthcare professional might look at delays in prescription or dispensing events to detect poor adherence. By excluding situations of regular refills (suggesting perfect implementation) and very late refills of over 90 days (suggesting non-persistence), we examined those intervals in which a delay in refill could have been associated with simultaneous or consecutive RDAC. 
Another strength of this study was the use of prescription data from over 350 practices across the UK. The database provided a large sample of patients, enabling a thorough analysis. However, prescription data have their own limitations. The clinician can prescribe the medication, but the patient may decide not to collect the medication at the pharmacy or, if collected, not to initiate the medication therapy or to persist with its use. Electronic monitoring (which is the closest to a golden standard for adherence measurement) would more accurately describe adherence patterns of patients. However, this method is less feasible in larger studies.
Asthma control (based on symptoms) and RDAC (based on healthcare utilization) are two different concepts. People might control their symptoms with other strategies (e.g. avoidance of triggers) or they may access healthcare without an increase in symptoms (e.g. pre-emptive prescription of oral corticosteroids, antibiotics). Multiple sources of variation are not recorded in the used database. This information needs to be collected more directly, although this would mean a more obtrusive way of gaining data.
The final sample included in the analyses comprised 10,472 patients, about one third of the total sample. Although this appears to be a substantial number of excluded patients, it needs to be emphasized that, to be able to accurately and robustly study variation in medication taking behavior resembling real-life routine behavior, it is important to ensure use of high quality data specific to this objective to achieve internal validity. This was also an important conclusion of the pre-study of Souverein  ADDIN EN.CITE (17). ICS implementation intervals of 100% (59% of all intervals) were excluded as it is not tenable to assume that these intervals reflected periods of perfect medication usage as most preceded a gap interval (an interval for which the number of days between two successive ICS prescriptions exceeded 90 days). Although the cut-off point of 90 days seems appropriate  ADDIN EN.CITE (17), it remains unclear how the medication was taken during the 100% interval. The dataset also contained a substantial proportion of gap intervals (15% of all intervals), in which it also is unclear how patients actually used the medication. Including these intervals in the analyses would make interpretation of the results difficult. Therefore, we considered it more appropriate to exclude these intervals to provide a more robust analysis and interpretation. However, this choice might limit the generalizability of the results.

Implications for research and practice
Our findings suggest that factors other than ICS implementation need to be considered to help explain variation in asthma outcomes, reinforcing the conclusions of Dima et al’s Asthma Care Model  ADDIN EN.CITE (31). The triggers patients are exposed to in real life, how they manage these, monitor symptoms and react to worsening symptoms, for example, are important aspects of real-world asthma management  ADDIN EN.CITE (31) and should be taken into account in long-term asthma care and further research in this domain.

Conclusions
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Table 1. Socio-demographic and clinical characteristics of the study population 
	Study populationN = 10,472	Excluded for analysisN = 3,450
General characteristics		
Male gender, % (n)	48.5 (5,078) 	49.3 (1,701)
Age, mean (SD)	39.2 (20.3)	42.2 (20.0)***
Index of Multiple Deprivation, % (n)	N=8,312	N=2,637
   Q1 (most affluent)	18.5 (1,539 )	17.0 (448)* 
   Q2	23.1 (1,918) 	22.8 (601)
   Q3	23.3 (1,940)	22.0 (581)
   Q4	20.2 (1,675)	21.0 (553)
   Q5 (most deprived)	14.9 (1,240)	17.2 (454)
Smoking status, % (n)	N=6,060	N=2,161
   Current	25.9 (1,569)	28.1 (607)
   Former	19.4 (1,176)	19.9 (429)
   Non	54.7 (3,315)	52.1 (1,125)
Clinical characteristics		
BMI, mean (SD)	26.3 (6.3)	27.1 (6.3)**
Charlson Comorbidity Index, mean (SD)	4.5 (2.8)	4.8 (3.3)**
Diagnosis rhinitis, % (n)	2.6 (272)	2.9 (99)
Diagnosis allergic rhinitis, % (n) 	9.2 (960)	8.8 (303)
Diagnosis hay fever, % (n)	6.1 (642)	6.2 (215)
Diagnosis COPD, % (n)	2.4 (253)	5.2 (180)***
Diagnosis other respiratory diseases , % (n)	0.3 (34)	0.4 (14)
Diagnosis GERD, % (n)	2.2 (233)	2.8 (98)*
Medication use during previous year		
Short acting beta agonists (SABA), % (n)	53.7 (5,618)	58.2 (2,008)***
Beta blockers, % (n)	1.7 (175)	2.0 (70)
Cardiac drugs, % (n)	11.8 (1,233)	14.6 (505)***
Antidiabetic drugs, % (n)	2.4 (251)	3.6 (125)***
NSAIDs, % (n)	12.4 (1,298)	15.4 (530) ***
Paracetamol, % (n)	11.8 (1,235)	14.0 (482)**
GERD drugs, % (n)	4.7 (487)	6.6 (228) ***
Tricyclic antidepressants, % (n)	3.1 (320)	4.1 (142) **
Other antidepressants, % (n)	6.0 (629)	7.5 (260) **
BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; NSAIDs, nonsteroidal anti-inflammatory drugs; GERD, gastroesophageal reflux disease
Significance levels: * p<0.05. ** p<0.01; *** p<0.001






SABA overuse within interval (ref=no) 	0.98 (0.75-1.27)
SABA overuse previous interval (ref=no)	0.96 (0.75-1.22)
ICS implementation within interval	1.01 (1.00-1.01)**






   normal (18.5-25)	1.08 (0.57-2.07)
   overweight (25-30)	1.08 (0.56-2.09)
   obese (≥30)	0.90 (0.46-1.77)
   missing	1.30 (0.70-2.39)
Smoking history (ref=current)	
   none	1.47 (1.15-1.89)**
   former	1.61 (1.18-2.19)**
   missing	1.50 (1.16-1.95)
Index of Multiple Deprivation (ref=Q1 most affluent)	
   Q2	1.21 (0.83-1.77)
   Q3	1.26 (0.84-1.88)
   Q4	1.27 (0.85-1.90)
   Q5 (most deprived)	1.08 (0.70-1.66)
   missing	1.03 (0.71-1.52)
Diagnosed with (ref=no)	
   rhinitis	0.74 (0.45-1.21)
   allergic rhinitis	1.02 (0.74-1.39)
   hay fever	0.99 (0.69-1.44)
   COPD	0.52 (0.35-0.78)**
   GERD	0.68 (0.41-1.12)
   other respiratory diseases	0.33 (0.10-1.05)
Charlson Comorbidity Index (ref=low (≤4))	0.65 (0.50-0.85)**
	
ICS characteristics	
Type of ICS device (ref=dry powder inhaler)	
   metered dose inhaler	0.87 (0.61-1.24)
   breath-actuated inhaler	1.48 (0.57-3.90)
Doses in the device	1.00 (0.99-1.00)*








a Included  were intervals with ICS implementation ranging from 4.0-99.6%; thus intervals with 0% and 100% implementation were excluded
# ICC: intraclass correlation. This is the ratio of the between group variance and the total variance.
Significance levels: * p<0.05; ** p<0.01; *** p<0.001
SABA, short-acting beta agonists; RDAC, risk domain asthma control; ICS, inhaled corticosteroids; BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease.







Occurrence of ≥1: (ref=no)		
   Asthma-related hospitalizations 	-0.20 (12.0)	
   Respiratory-related hospitalizations 	-8.40 (11.2)	
   Asthma-related hospitalizations & emergency visits	-3.0 (15.3)	
   Prescriptions of acute OCS	-5.0 (9.0)	
   Prescription of antibiotics 	-1.77 (0.64)**	
   Asthma-related outpatient visits 	-2.32 (1.17)*	
   Moderate to severe exacerbationsc	3.04 (8.99)	
SABA overuse (ref=no) 	-6.68 (0.42)***	-6.69 (0.42)***
RDAC (ref=no)		2.18 (0.46)**
Previous interval		
Occurrence of ≥1: (ref=no)		
   Asthma-related hospitalizations 	0.41 (10.4)	
   Respiratory-related hospitalizations 	-2.80 (9.55)	
   Asthma-related hospitalizations & emergency visits	1.86 (12.5)	
   Prescriptions of acute OCS	-6.32 (7.77)	
   Prescription of antibiotics 	-0.97 (0.64)	
   Asthma-related outpatient visits 	-1.34 (1.19)	
   Moderate to severe exacerbations	6.21 (7.79)	





Gender (ref=female)	0.25 (0.36)	0.27 (0.36)
BMI (ref=underweight (<18.5))		
   normal (18.5-25)	-1.15 (1.28)	-1.10 (1.28)
   overweight (25-30)	0.59 (1.31)	0.65 (1.32)
   obese (≥30)	0.16(1.37)	0.20 (1.37)
   missing	-0.71 (1.19)	-0.67 (1.19)
Smoking history (ref=current)		
   none	-0.74 (0.58)	-0.73 (0.58)
   former	-1.01 (0.71)	-1.00 (0.71)
   missing	0.50 (0.59)	0.49 (0.59)
Index of Multiple Deprivation (ref=Q1 most affluent)		
   Q2	0.94 (0.88)	0.91 (0.88)
   Q3	2.05 (0.91)*	2.02 (0.91)*
   Q4	0.51 (0.91)	0.46 (0.91)
   Q5 (most deprived)	0.96 (0.98)	0.93 (0.98)
   missing	1.98 (0.86) 	1.94 (0.86)
Diagnosed with (ref=no)		
   rhinitis	-0.72 (1.10)	-0.74 (1.10)
   allergic rhinitis	-0.11 (0.64)	-0.12 (0.63)
   hay fever	-2.63 (0.79)***	-2.62 (0.79)***
   COPD	2.75 (1.10)*	2.59 (1.10)*
   GERD	0.33 (1.22)	0.33 (1.2)
   other respiratory diseases	1.35 (3.32)	1.30 (3.32)
Charlson Comorbidity Index (ref=low (≤4))	0.12 (0.65)	0.12 (0.65)
		
ICS characteristicsb		
Doses in the device	0.13 (0.0)***	0.13 (0.0)***
Prescribed daily doses	-3.88 (0.15)***	-3.87 (0.15)***
		
Random part	Variance (SE)	Variance (SE)
Between patients variance	89.96 (3.40)	89.82 (3.40)




a Included  were intervals with ICS implementation ranging from 4.0-99.6%; thus intervals with 0% and 100% implementation were excluded.
b Type of device was not added to the model because of lack of variation.
c Defined as having an asthma-related hospitalization or an asthma-related emergency visit or and OCS prescription with evidence of respiratory review
# ICC: intraclass correlation. This is the ratio of the between group variance and the total variance.
Significance levels: * p<0.05; ** p<0.01; *** p<0.001





Figure 1. Flowchart of study population for longitudinal analyses of ICS intake behavior.
Figure 2a. Illustration of intervals and calculation of ICS implementation, without carry-over. ICS prescription duration most often equaled 50 days and is therefore used in this Figure. 
Figure 2b. Illustration of intervals and calculation of ICS implementation, with carry-over. ICS prescription duration most often equaled 50 days and is therefore used in this Figure.
Figure 3. Diagram visualizing the bidirectional relationships tested with two separate multilevel models. In the first model RDAC is the dependent variable, in the second model this is ICS implementation.
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